WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer.
The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification in glioma, the most common form of brain cancer.
Brain cancer is the leading cause of death among children and young adults under age 20. This year, more than 200,000 people in the United States will be diagnosed with either a primary or metastatic brain tumor. There are more than 120 different types of brain tumors, making specific diagnosis and effective treatment extremely complicated. In many cases, accessing brain tissue via biopsy carries significant risk or is not surgically feasible. The ability to sample a brain cancer's genetic characteristics through a blood or cerebrospinal fluid sample could contribute greatly to driving advances in clinical treatment and drug development.
This collaboration will bring together world-leading clinicians, researchers and industry participants to develop the potential of stable, high-quality disease-specific RNA harvested from exosomes found in blood and cerebrospinal fluid. The joint effort will support near-term, in-vitro diagnostic validation of known tumor and immune-derived clinical biomarkers for brain cancer.
"We are impressed with the catalytic approach of Exosome Diagnostics and our academic partners," said Max Wallace, chief executive officer of Accelerate Brain Cancer Cure. "The ability to identify and track specific pathway mutations over time could significantly improve brain cancer patient care."
As early as 2007, Exosome Diagnostics' researchers f
|SOURCE Exosome Diagnostics; Accelerate Brain Cancer Cure|
Copyright©2010 PR Newswire.
All rights reserved